This Laboratory Program will provide natural product samples for the NCNPDDG. A total of 1,000 blue-green algae (cyanobacteria) will be extracted each year with both a lipophilic and a hydrophilic solvent system. These extracts will be submitted to Wayne State University for analysis. Extracts which exhibit solid tumor and/or tumor selective activity will be fractionated so that the active compound can be purified and identified. Highest priority will be given to those extracts that are active against drug-resistant solid tumors. We expect that about 0.5% of the extracts will demonstrate activity worth pursuing. Scale-up batches will then be pursued to provide sufficient material for in vivo testing. The identified active component will initiate an analog synthesis program as well as a search through the inventories of both Eli Lilly and NCI for analogs to test. Approximately 1 purified compound per year is expected to begin pharmacological studies as well as mechanism of action studies.
| Cruz-Rivera, Edwin; Friedlander, Michael (2011) Feeding preferences of mesograzers on aquacultured Gracilaria and sympatric algae. Aquaculture 322:218-222 |
| Boinpally, Ramesh R; Polin, Lisa; Zhou, Sen-Lin et al. (2003) Pharmacokinetics and tissue distribution of cryptophycin 52 (C-52) epoxide and cryptophycin 55 (C-55) chlorohydrin in mice with subcutaneous tumors. Cancer Chemother Pharmacol 52:25-33 |
